О письме
McKinsey & Company отправил это письмо 12 января 2025, 23:15. Тема: «A comprehensive approach to biopharma R&D transformation». В архиве Валеры письмо сохранено как скриншот рассылки с адреса publishing@email.mckinsey.com. Ниже — краткий текстовый фрагмент для ознакомления и полный вид письма на скриншоте.
Текст письма
McKinsey & Company Share this email New from McKinsey & Company The 8 ingredients to biopharma R&D productivity
As biopharmaceutical R&D organizations face pressure to boost productivity, pharma leaders are turning to advanced technologies to reshape operations and deliver new efficiencies. Leading companies are already reaping benefits from well-designed tech stacks , but the industry’s overall R&D productivity has been mostly flat, write McKinsey’s Jeffrey Lewis and Joachim Bleys .
For eight ingredients to achieve sustained performance growth, explore “ RewiR&D: Making more medicines that matter ,” a special collection of recently published articles that offer practical solutions to biopharmaceutical innovation challenges. Together, these articles provide a recipe to boost R&D productivity and accelerate the development of lifesaving therapies.
Полный вид письма — на скриншоте.
Кнопки и ссылки в письме
- Jeffrey Lewis
- and
- Joachim Bleys
- Read more
- Break the cycle
